We appreciate the constructive dialogue from Cheng on our study’s findings.1 We agree that any clinical database study has limitations that necessitate careful interpretation of results. Manual medical records review is a logical next step to mitigate these shortcomings and allow a more thorough examination of each patient’s course. Nevertheless, we re-analysed our data in response to points raised. The analyses in our original paper suggest an elevated risk of undergoing an esophagogastroduodenoscopy (EGD) in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RA) compared with control. As mentioned in our prior reply,2 we recognise that there is a potential diagnostic bias from this observation. We re-ran our cohorts and found that the rate of undergoing an EGD in the propensity-score matched cohort receiving short-acting GLP-1 RA was …

中文翻译：

---

作者回复： 探讨短效 GLP-1 受体激动剂对 GERD 风险的影响


我们感谢 Cheng 就我们的研究结果进行的建设性对话。我们同意任何临床数据库研究都有局限性，需要仔细解释结果。手动病历审查是减轻这些缺点并允许对每位患者的病程进行更彻底检查的合乎逻辑的下一步。尽管如此，我们还是根据提出的观点重新分析了我们的数据。我们原始论文中的分析表明，与对照组相比，接受胰高血糖素样肽-1 受体激动剂 （GLP-1 RA） 治疗的患者接受食管胃十二指肠镜检查 （EGD） 的风险升高。正如我们之前的回复中提到的，2 我们认识到这一观察存在潜在的诊断偏差。我们重新运行了我们的队列，发现在接受短效 GLP-1 RA 的倾向评分匹配的队列中接受 EGD 的比率是......